phase readout
savePhase 3 primary completion: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
November 11, 2026updated 1mo ago
community read0 votes
Sponsor: AstraZeneca. Status: Active, not recruiting. Conditions: Breast Cancer; HER2-positive; Metastatic. NCT04784715.
view source ↗Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that